The uptake of nucleosides by mammalian cells is complex and mediated by multiple transport proteins. As data increases on the properties of these transporters it is becoming increasingly clear that there are differences in their substrate specificity and sensitivity to inhibitors. Furthermore, there are differences in the distribution of the transporters between some tumors and normal tissues that might be exploited in chemotherapy. One of the most striking is the presence of Na+-dependent, concentrative transport in several normal tissues, but not in most tumor cells. Since Na+- dependent nucleoside transporters are not inhibited by NBMPR or dipyridamole (inhibitors of the two equilibrative transporters found in most tumor cells), there is potential for the modulation of antimetabolite activity with these inhibitors.
Aim 1 of this project will further define the nucleoside transport activities present in critical normal tissues such as intestine and bone marrow, and changes that may occur in nucleoside transport during differentiation of intestinal cells.
The second aim of this project will test the hypothesis that highly selective therapy can be developed for some, but not all, tumors using inhibitors of de novo pyrimidine biosynthesis in combination with transport inhibitors to block nucleoside salvage. This therapeutic approach is predicted to be effective against tumors with predominantly NBMPR-sensitive nucleoside transport, but not against tumors with significant levels of NBMPR-insensitive transport. The mouse L1210 leukemia, which has three of the four known nucleoside transporters, and sublines of L1210 that are deficient in one or more of the transporters will be used as a model. This will allow us to evaluate the role of each of the transporters in tumor response against a common background with respect to other factors that may affect drug activity.
The third aim will test the hypothesis that selective therapy can be developed for tumors with NBMPR-insensitive nucleoside transport using a cytotoxic nucleoside analog in combination with a transport inhibitor to block uptake of the analog by normal tissues. This will again be done using L1210 tumor model to determine the role of each of the transporters in the success or failure of therapy. The last aim will apply these therapeutic approaches to human tumors that grow as xenografts in immune deprived mice and as cell lines in culture. The in vitro/in vivo model will again permit us to examine at the biochemical level reasons for success or failure of the therapeutic strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA055056-02
Application #
3199493
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1991-07-01
Project End
1996-04-30
Budget Start
1992-05-01
Budget End
1993-04-30
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Patel, D H; Crawford, C R; Naeve, C W et al. (2000) Cloning, genomic organization and chromosomal localization of the gene encoding the murine sodium-dependent, purine-selective, concentrative nucleoside transporter (CNT2). Gene 242:51-8
Patel, D H; Allay, J A; Belt, J A et al. (2000) Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells. Blood 95:2356-63
Crawford, C R; Patel, D H; Naeve, C et al. (1998) Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 273:5288-93
Mackey, J R; Mani, R S; Selner, M et al. (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-57
Crawford, C R; Cass, C E; Young, J D et al. (1998) Stable expression of a recombinant sodium-dependent, pyrimidine-selective nucleoside transporter (CNT1) in a transport-deficient mouse leukemia cell line. Biochem Cell Biol 76:843-51
Long, B H; Carboni, J M; Wasserman, A J et al. (1998) Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 58:1111-5
Allay, J A; Spencer, H T; Wilkinson, S L et al. (1997) Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90:3546-54
Belt, J A; Marina, N M; Phelps, D A et al. (1993) Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 33:235-52
Cory, J G; Downes, D L; Ng, C Y et al. (1992) 5-hexyl-2'-deoxyuridine inhibition of nucleoside transport in L1210 cells. Oncol Res 4:175-9
Marina, N M; Belt, J A (1991) Effect of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocyte-macrophage progenitor cells. Cancer Commun 3:367-72